Iambic

What Iambic does

Iambic Therapeutics is a clinical-stage, privately held biotechnology company headquartered in San Diego, California, with additional offices in Boston and Cambridge, UK, founded in 2019/2020 by Tom Miller, PhD (CEO) and Fred Manby, PhD (CTO). The company is developing an integrated AI-driven drug discovery platform that combines two proprietary AI technologies — Enchant, a multi-modal transformer that predicts clinical outcomes from early-stage molecular data, and NeuralPLexer, a generative AI model for protein-ligand complex structure prediction — with an automated high-throughput wet lab that generates proprietary biological data on a weekly cadence. Iambic's internal pipeline includes IAM1363, a selective brain-penetrant HER2 inhibitor that entered Phase 1 in March 2024 (approximately 2 years from discovery, versus a 6-year industry benchmark), as well as preclinical candidates IAM-K1 (KIF18A inhibitor) and IAM-C1 (CDK2/4 inhibitor). The company has been recognized on the CNBC Disruptor 50 list in 2025 and 2026.

Iambic operates a B2B enterprise model, partnering with large pharmaceutical companies through multi-year collaboration agreements rather than selling discrete products. Revenue is generated through upfront payments, research funding, technology access fees, milestone payments, and royalties on net sales of any partnered products. Named partners include Takeda (a February 2026 collaboration potentially exceeding $1.7B in milestone and royalty value for oncology and GI/inflammation), Bayer (a June 2026 sourcing collaboration for small molecule discovery), Jazz Pharmaceuticals (HER2 combination therapy in HER2-positive breast cancer), Revolution Medicines (technology collaboration using NeuralPLexer), Lundbeck (migraine drug discovery), and Lambda AI (next-generation AI infrastructure). The company is venture-backed, with over $350M raised from institutional investors including Abingworth, Sequoia Capital, Mubadala Capital, Exor Ventures, Qatar Investment Authority, Alexandria Venture Investments, the Ireland Strategic Investment Fund, and NVIDIA, and employs more than 140 people across its three sites.

Name

Iambic

Legal name

Iambic Therapeutics, Inc.

Website

https://iambic.ai

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

101–250 employees

Short description

Iambic Therapeutics is a clinical-stage biotech using proprietary AI platforms (Enchant and NeuralPLexer) integrated with an automated wet lab to discover and develop small molecule therapeutics, partnering with large pharmaceutical companies such as Takeda, Bayer, and Jazz Pharmaceuticals.

Ownership category

akta.pro rank

Product category

AI-driven drug discovery platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• AI drug discovery
• Computational biology
• Small molecule therapeutics
• Precision oncology
• Machine learning pharma

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Partnership Milestone Payments: Iambic receives upfront payments, research funding, technology access fees, and success-based milestone payments from pharmaceutical partners. The Takeda deal alone could generate over $1.7 billion in potential payments plus royalties on net sales.
2. Technology Platform Licensing: Partners gain access to Iambic's AI platforms (Enchant, NeuralPLexer) for drug discovery programs, generating technology access fees and ongoing collaboration payments.
3. Royalty Payments: Iambic receives royalties on net sales of any products developed through partnership agreements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Iambic Therapeutics is a clinical-stage biotechnology company that develops an AI-driven drug discovery platform combining proprietary transformer models (Enchant) and protein-ligand structure prediction (NeuralPLexer) with automated high-throughput wet-lab experimentation. The company advances an internal pipeline of differentiated small-molecule oncology candidates (IAM1363, IAM-K1, IAM-C1) and licenses its AI platform to large pharmaceutical companies through multi-year collaboration agreements.

Product overview

Iambic Therapeutics operates as a clinical-stage life science and technology company offering an integrated AI-driven drug discovery platform. The core platform combines two proprietary AI technologies—Enchant (a multi-modal transformer for predicting clinical outcomes) and NeuralPLexer (for protein-ligand structure prediction)—with automated high-throughput experimentation capabilities. The company advances a pipeline of clinical and preclinical assets including IAM1363 (Phase 1 HER2 inhibitor), IAM-K1 (KIF18A inhibitor), and IAM-C1 (CDK2/4 inhibitor), while providing partners access to its industry-leading AI technologies for small molecule drug discovery.

Differentiator

Problem solved

Functional benefit

Products and services

• Enchant A multi-modal transformer AI platform that predicts clinical outcomes from the earliest stages of drug discovery. It integrates physics principles with machine learning to break down data barriers between preclinical and clinical research, and is licensed to pharmaceutical partners for small molecule design.
• NeuralPLexer A generative AI model for protein-ligand complex structure prediction that uses neural network models to predict how drug molecules bind to proteins, enabling rapid identification of differentiated molecules for drug discovery. Licensed to partners such as Takeda and Bayer.
• AI-Driven Drug Discovery Platform An integrated platform combining proprietary AI technologies (Enchant and NeuralPLexer) with automated high-throughput experimentation capabilities that converts novel molecular designs into biological insights weekly, enabling delivery of differentiated clinical candidates at accelerated timelines.
• IAM1363 A highly selective, brain-penetrant Type II HER2 inhibitor for HER2-driven cancers that has demonstrated anti-tumor activity, safety and tolerability in Phase 1b studies. Being evaluated in combination with zanidatamab for HER2-positive breast cancer in collaboration with Jazz Pharmaceuticals.
• IAM-K1 A potential best-in-class, brain-penetrant inhibitor targeting KIF18A for breast cancer, ovarian cancer, and other solid tumors.
• IAM-C1 A potent, highly selective CDK2/4 small-molecule inhibitor for HR+/HER2- metastatic breast cancer, representing a potential first-in-class program.

Quantifiable outcome

• Compressed drug discovery timeline from 6 years to under 2 years
• +2 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core and secondary.

• BayercoreStrategic or Co-development Partner · 22 June 2026Sourcing partnership leveraging Iambic's AI-powered Enchant and NeuralPLexer platforms for small molecule drug discovery and development. Collaboration aims to identify new drug pathways, accelerate optimization timelines, and improve decision-making across Bayer's R&D value chain.
• Takeda PharmaceuticalscoreStrategic or Co-development Partner · 9 February 2026Multi-year collaboration to advance AI-driven design of small molecules for oncology and gastrointestinal/inflammation therapeutic areas. Iambic will receive upfront payments, research funding, technology access fees, and success-based milestone payments potentially exceeding $1.7 billion, plus royalties on net sales of any products developed.
• Jazz PharmaceuticalssecondaryStrategic or Co-development Partner · 21 October 2025Research collaboration evaluating IAM1363 (HER2 inhibitor) and zanidatamab combination for HER2-positive breast cancer patients previously treated with trastuzumab deruxtecan.
• Revolution MedicinessecondaryTechnology or Integration · 9 July 2025Technology and research collaboration using Iambic's AI discovery tools (NeuralPLexer) to pursue new drug candidates. Revolution Medicines gained access to Iambic's platform for target prediction.
• LundbecksecondaryStrategic or Co-development Partner · 27 September 2024AI drug discovery collaboration focused on treatments for migraine. Part of Lundbeck's strategy to integrate AI across its drug discovery operations.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Exscientia: Pioneer in AI-driven small-molecule drug design with multiple pharma partnerships (Bayer, Sanofi, GSK). Directly comparable technology focus (small-molecule AI design) and partnership GTM.
• Atomwise: AI-driven small-molecule discovery platform with multi-pharma partnerships. Comparable technology approach (structure-based ML) and licensing/collaboration business model.
• Schrödinger, Inc. Physics-based computational chemistry and ML platform for drug discovery, with both internal pipeline and pharma software licensing. Comparable platform-plus-pipeline model.
• Recursion Pharmaceuticals: Clinical-stage AI-driven drug discovery company combining high-throughput biology with ML. Most directly comparable to Iambic in combining proprietary AI platforms with integrated wet-lab automation and pharma partnerships (e.g., Roche/Genentech, Bayer).
• Genesis Therapeutics: AI-native biotech combining foundation models and physics-based methods for small-molecule discovery. Closely comparable platform architecture to Iambic's NeuralPLexer/Enchant approach.
• Insitro: AI-driven drug discovery company using ML on proprietary high-throughput biological data. Targets similar pharma partnership business model and competes for the same enterprise pharma customer base.
• BenevolentAI: AI drug discovery company using ML on biomedical knowledge graphs to identify targets and drug candidates. Comparable AI-discovery-to-clinical-pipeline model.
• XtalPi: AI + robotics-driven drug discovery company with extensive pharma partnerships. Comparable combination of predictive AI and automated experimentation to accelerate small-molecule discovery.
• Isomorphic Labs: Alphabet-owned AI drug discovery company spun out of DeepMind. Competes head-to-head for pharma AI partnerships and uses similar transformer and protein-structure-prediction approaches (AlphaFold lineage).

Broad incumbents

• NVIDIA BioNeMo / Clara Discovery: While NVIDIA is a tech incumbent and a Iambic investor, its BioNeMo/Clara platform provides AI drug-discovery foundation models and infrastructure that increasingly compete with or commoditize platform-layer offerings like Enchant/NeuralPLexer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/iambic_ai
• LinkedInlinkedin.com/company/iambic-ai

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds5 records

Investors25 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Iambic